Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $67
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $65 to $67.
May 23, 2023 | 9:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines and raises the price target from $65 to $67.
The raised price target by Needham analyst Ami Fadia indicates a positive outlook for Blueprint Medicines. This news is likely to have a positive impact on the stock price in the short term as it shows increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100